WHO and World Bank to examine effect of global initiatives
This article was originally published in Scrip
The World Health Organization (WHO) and the World Bank will jointly examine the effect of global disease-specific health initiatives in low- and middle-income countries. The move is after critics argued that they (the organizations?) were eroding already weak health systems. The two organisations will work with country officials, academic and research institutions, global health initiatives and civil society organisations to address whether global health initiatives are weakening systems or if health systems are preventing the progress of the initiatives and undermining investments. The collaboration will examine and combine the strengths of different approaches of initiatives to achieve better results from funding and improve health. There are currently more than 80 global health initiatives, including the GAVI Alliance, PEPFAR and the Global Fund.
You may also be interested in...
The Indian pharmaceutical sector is recognised for its entrepreneurial spirit. Many companies have crafted successful business strategies by offering API manufacturing, drug discovery, CRAMS and other services to global pharmaceutical customers. Others market their products overseas while leveraging growth opportunities on their home turf. The following five domestic companies are well worth watching in 2011.
The Swedish biotech firm Active Biotech has appointed Dr Helén Tuvesson as its new chief scientific officer, effective 1 April. Dr Tuvesson has been with the company since 1998, working in preclinical development, R&D management and most recently within the senior management team. She will report to president and CEO Tomas Leanderson.
Affimed Therapeutics (Germany) has appointed Dr Adi Hoess as its new chief commercial officer. Effective immediately, Mr Hoess will focus on commercial and strategic management and business development, complimenting his previous senior management and business development roles at Jenowis, Carl Zeiss Jena, MorphoSys and Jerini. His appointment also coincides with the continued development of the company's lead product candidate, AFM13, for Hodgkin's lymphoma, which entered a Phase I clinical trial last November (scripintelligence.com, 15 November 2010).